• To determine the incidence of complete and partial response and the duration of response in patients with recurrent or resistant Hodgkin's Disease (HD) treated with sequential administration of oral 6-Thioguanine (6-TG) after IV Methotrexate (MTX). [ Time Frame: Conclusion of the study ] [ Designated as safety issue: No ]
  

• Define Toxicity of this sequential drug combination. [ Time Frame: Conclusion of study ] [ Designated as safety issue: Yes ]
  

Inclusion Criteria:

• Patients with histologic proof of HD who are in relapse and have failed >_ 2 prior chemotherapy regimens.
• Patients must have a life expectancy of at least 8 weeks.
• All patients must have ECOG performance level rating of<_ 2.
• Patients or their parents (guardian) must sign an informed consent indicating that they are aware of the investigational nature of the study.
• Patients must have recovered from the toxic effects of prior therapy before entering this study or at least 2 weeks should have elapsed since the end of last course of CT.
• Patients must have adequate liver function (bilimbin <_ 2.0 mg/dl, SGOT less than 1.5 times normal (unless it is due to disease), adequate renal function (creatinine _< 1.5 mg/dl, creatinine clearance >_ 60 ml/min/1.73 m2).
• Patients should have a granulocyte count >_500/gL and a platelet count >_ 100,000/uL (unless due to disease involvement of the bone marrow).
• Male and female patients of child-bearing age should use effective methods of contraception, if sexually active.

Exclusion Criteria:

• Patients with active infections or significant medical conditions other than their malignancy shall be excluded.
• Patients with HD who had prior MTX or 6-TG should be excluded.